Short Interest in Cardiff Oncology, Inc. Decreases By 11.5

CRDF Stock  USD 3.78  1.34  54.92%   
Roughly 67% of Cardiff Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Cardiff Oncology suggests that many traders are alarmed. The current market sentiment, together with Cardiff Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Cardiff Oncology stock news signals to limit their universe of possible portfolio assets.
  
Cardiff Oncology, Inc. was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 801,300 shares, a decrease of 11.5 percent from the January 31st total of 905,900 shares. Based on an average daily volume of 240,600 shares, the

Read at thelincolnianonline.com
news
  

Cardiff Oncology Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Cardiff Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Cardiff Oncology Fundamental Analysis

We analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Cardiff Oncology is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Cardiff Oncology Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cardiff Oncology stock to make a market-neutral strategy. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics with similar companies.

Peers

Cardiff Oncology Related Equities

RVPHWReviva Pharmaceuticals   19.05   
0%
100.0%
RVPHReviva Pharmaceuticals   18.87   
0%
99.0%
RNAZTranscode Therapeutics   12.22   
0%
64.0%
CUECue Biopharma   3.64   
0%
19.0%
MREOMereo BioPharma   1.58   
0%
8.0%
CGTXCognition Therapeutics   0.93   
0%
4.0%
LYRALyra Therapeutics   0.48   
0%
2.0%
BOLTBolt Biotherapeutics   0.18   
0%
1.0%
NLSPNLS Pharmaceutics   1.00   
5.0%
0%
CGEMCullinan Oncology   1.18   
6.0%
0%
KODKodiak Sciences   1.48   
7.0%
0%
INABIn8bio   1.61   
8.0%
0%
DAWNDay One   1.86   
9.0%
0%
PDSBPDS Biotechnology   2.28   
11.0%
0%
AUTLAutolus Therapeutics   2.71   
14.0%
0%
LTRNLantern Pharma   4.10   
21.0%
0%
SLSSellas Life   4.59   
24.0%
0%

Complementary Tools for Cardiff Stock analysis

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance